FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W93486501> ?p ?o ?g. }

• W93486501 endingPage "22" @default.
• W93486501 startingPage "215" @default.
• W93486501 abstract "Lopinavir/ritonavir has been the recommended boosted protease inhibitor for treatment-naive individuals in all guidelines since its approval in the year 2000. More recently, the rest of ritonavir-boosted protease inhibitors (namely lopinavir once-daily, fosamprenavir, saquinavir, atazanavir, and darunavir) have demonstrated non-inferior antiviral efficacy at 48 weeks than lopinavir twice-daily. Overall, all ritonavir-boosted protease inhibitors display a high genetic and pharmacological barrier to resistance development and protect the rest of the drugs on board in the regimen, achieving similar CD4 count gains among them. During the last year, studies conducted with atazanavir and darunavir have demonstrated superior virologic efficacy against lopinavir at 96 weeks in their pivotal trials. These two protease inhibitors provide significant improvements in triglycerides and gastrointestinal toxicity, together with simpler once-daily formulations, compared to lopinavir. In the case of atazanavir, this is mainly driven by a lower rate of discontinuations due to drug-related side effects, as pure antiviral efficacy is essentially similar to lopinavir. Furthermore, the gastrointestinal intolerance of lopinavir is actually compensated by an increased risk of hyperbilirubinemia and jaundice with atazanavir, but this is more a cosmetic problem and rarely a cause of drug withdrawal. Darunavir has been licensed to be taken once-daily in treatment-naive patients, and shows significantly better lipid and gastrointestinal tolerance than lopinavir. Robust sensitivity analysis with darunavir prove superior antiviral efficacy than lopinavir at 96 weeks also when non-virologic failures (toxicity and discontinuations) are censored, or when only patients receiving lopinavir twice-daily are included in the estimation. Moreover, darunavir has shown superior antiviral efficacy than lopinavir, particularly in three situations of particular clinical concern: high baseline viral load, low baseline CD4 counts, and suboptimal drug adherence. Over the last years, the treatment landscape with ritonavir-boosted protease inhibitors as initial HIV therapy has accomplished significant advances, with improved degrees of efficacy, tolerability, and convenience, that should be used to guide treatment choice in first-line antiretroviral therapy." @default.
• W93486501 created "2016-06-24" @default.
• W93486501 creator A5029931096 @default.
• W93486501 date "2009-11-27" @default.
• W93486501 modified "2023-09-23" @default.
• W93486501 title "First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing better." @default.
• W93486501 cites W1572621932 @default.
• W93486501 cites W1582887581 @default.
• W93486501 cites W1968485058 @default.
• W93486501 cites W1975974254 @default.
• W93486501 cites W1976627773 @default.
• W93486501 cites W1986248827 @default.
• W93486501 cites W2001551451 @default.
• W93486501 cites W2021038940 @default.
• W93486501 cites W2049167103 @default.
• W93486501 cites W2052991207 @default.
• W93486501 cites W2076339980 @default.
• W93486501 cites W2080396587 @default.
• W93486501 cites W2085088518 @default.
• W93486501 cites W2088221871 @default.
• W93486501 cites W2099509337 @default.
• W93486501 cites W2099697190 @default.
• W93486501 cites W2103513664 @default.
• W93486501 cites W2109350540 @default.
• W93486501 cites W2119433625 @default.
• W93486501 cites W2131867753 @default.
• W93486501 cites W2133758885 @default.
• W93486501 cites W2139772076 @default.
• W93486501 cites W2145186026 @default.
• W93486501 cites W2148750104 @default.
• W93486501 cites W2149950973 @default.
• W93486501 cites W2154881336 @default.
• W93486501 cites W2171236519 @default.
• W93486501 cites W2171764043 @default.
• W93486501 cites W2182777591 @default.
• W93486501 cites W2278131590 @default.
• W93486501 cites W2309089862 @default.
• W93486501 cites W2416045060 @default.
• W93486501 cites W305241044 @default.
• W93486501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19940948" @default.
• W93486501 hasPublicationYear "2009" @default.
• W93486501 type Work @default.
• W93486501 sameAs 93486501 @default.
• W93486501 citedByCount "7" @default.
• W93486501 countsByYear W934865012014 @default.
• W93486501 countsByYear W934865012015 @default.
• W93486501 countsByYear W934865012016 @default.
• W93486501 crossrefType "journal-article" @default.
• W93486501 hasAuthorship W93486501A5029931096 @default.
• W93486501 hasConcept C126322002 @default.
• W93486501 hasConcept C142462285 @default.
• W93486501 hasConcept C159047783 @default.
• W93486501 hasConcept C2777182164 @default.
• W93486501 hasConcept C2778414717 @default.
• W93486501 hasConcept C2779182219 @default.
• W93486501 hasConcept C2779298103 @default.
• W93486501 hasConcept C2780404665 @default.
• W93486501 hasConcept C2781413609 @default.
• W93486501 hasConcept C2993143319 @default.
• W93486501 hasConcept C3013748606 @default.
• W93486501 hasConcept C71924100 @default.
• W93486501 hasConcept C98274493 @default.
• W93486501 hasConceptScore W93486501C126322002 @default.
• W93486501 hasConceptScore W93486501C142462285 @default.
• W93486501 hasConceptScore W93486501C159047783 @default.
• W93486501 hasConceptScore W93486501C2777182164 @default.
• W93486501 hasConceptScore W93486501C2778414717 @default.
• W93486501 hasConceptScore W93486501C2779182219 @default.
• W93486501 hasConceptScore W93486501C2779298103 @default.
• W93486501 hasConceptScore W93486501C2780404665 @default.
• W93486501 hasConceptScore W93486501C2781413609 @default.
• W93486501 hasConceptScore W93486501C2993143319 @default.
• W93486501 hasConceptScore W93486501C3013748606 @default.
• W93486501 hasConceptScore W93486501C71924100 @default.
• W93486501 hasConceptScore W93486501C98274493 @default.
• W93486501 hasIssue "4" @default.
• W93486501 hasLocation W934865011 @default.
• W93486501 hasOpenAccess W93486501 @default.
• W93486501 hasPrimaryLocation W934865011 @default.
• W93486501 hasRelatedWork W1993133133 @default.
• W93486501 hasRelatedWork W2002479472 @default.
• W93486501 hasRelatedWork W2014282717 @default.
• W93486501 hasRelatedWork W2018313155 @default.
• W93486501 hasRelatedWork W2034615934 @default.
• W93486501 hasRelatedWork W2047658510 @default.
• W93486501 hasRelatedWork W2059564465 @default.
• W93486501 hasRelatedWork W2061558739 @default.
• W93486501 hasRelatedWork W2079834621 @default.
• W93486501 hasRelatedWork W2088167147 @default.
• W93486501 hasRelatedWork W2111376288 @default.
• W93486501 hasRelatedWork W2139662982 @default.
• W93486501 hasRelatedWork W2139772076 @default.
• W93486501 hasRelatedWork W2145125431 @default.
• W93486501 hasRelatedWork W2148750104 @default.
• W93486501 hasRelatedWork W2150504993 @default.
• W93486501 hasRelatedWork W2171236519 @default.
• W93486501 hasRelatedWork W2991980021 @default.
• W93486501 hasRelatedWork W3196425679 @default.

• next